A Systematic Review of the Economic and Humanistic Burden of Gout. - Wikidata - wikimedia - TriplyDB

A Systematic Review of the Economic and Humanistic Burden of Gout.

A Systematic Review of the Economic and Humanistic Burden of Gout.

http://www.wikidata.org/entity/Q35629910

about

Gout Classification Criteria: Update and Implications Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis.Hyperuricemia in Tendons.Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site.Association of gout and depression: A systematic review and meta-analysis.The American College of Physicians and the 2017 guideline for the management of acute and recurrent gout: treat to avoiding symptoms versus treat to target.A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout.Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)

P2860

Q26747158-0C613CA1-2B3F-4DA1-85D3-23F7F52A595D Q36029222-AD3E4933-848B-485C-AF38-09ADD0C997BF Q37307966-C4D68753-C883-42EE-ACA7-08D6C08AC857 Q38669137-13FF5B19-BBDD-439A-900B-5EC215CA2208 Q39480194-E27E18D9-4514-41D5-AB76-4E48B8B0E046 Q40600650-6174A7BA-2D12-4A50-B4D0-E06A4934BF69 Q47766532-35C66FCC-3284-4EE0-926B-54C8CF372318 Q50050657-ADF5B97B-9F6E-43D3-A75C-FD7C23388D62 Q51741961-A9678276-F7F1-4C64-BB0A-2F8C1932D6A1 Q56637250-3F803617-2400-4C52-802A-5F2F8B9323B0

P2860

A Systematic Review of the Economic and Humanistic Burden of Gout.

http://www.wikidata.org/entity/Q35629910

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A Systematic Review of the Economic and Humanistic Burden of Gout.

@ast

A Systematic Review of the Economic and Humanistic Burden of Gout.

@en

type

label

A Systematic Review of the Economic and Humanistic Burden of Gout.

@ast

A Systematic Review of the Economic and Humanistic Burden of Gout.

@en

prefLabel

A Systematic Review of the Economic and Humanistic Burden of Gout.

@ast

A Systematic Review of the Economic and Humanistic Burden of Gout.

@en

P1433

Q35629910-CE7257FE-1715-4945-8309-B91626DA52CF

P1476

Q35629910-D813A58A-EAC7-45EA-BA4D-DC9C7B106D15

P2093

Q35629910-8FEA530D-F62F-4825-B20C-8FE5C7E3E654

P2860

Q35629910-03427205-3376-440B-8F4D-44D9196E288E

Q35629910-0B1A5996-8BE5-4F0D-AA05-2D292A0F544E

Q35629910-1119F1F7-A8D5-4927-8ABF-E4E5C6A53DA4

Q35629910-1456055C-9481-4E63-BDD9-0F74117BFF93

Q35629910-150B407A-F3E7-4A3A-A4DC-235D36C16039

Q35629910-19060890-66EF-489B-B0FE-F400245E4232

Q35629910-1909BF9B-3B83-4708-BAC5-B03B028803BE

Q35629910-193DB1B7-C735-4F84-98E6-DFBDEB2DB0A1

Q35629910-1A1B10B7-85F8-4A55-B26E-0D1346E4CCD4

Q35629910-1DF4072B-4163-4AD5-9C3E-C7BC2A0482B7

P2888

Q35629910-A6FFFACB-BAC7-48D4-A4E1-F4E5B5018835

P304

Q35629910-7A4F0389-17DD-4B37-B2C8-C6F10136CBC0

P31

Q35629910-4A6DE895-ED0F-48D4-A72B-D983E9362738

P356

Q35629910-86CB5FAE-1362-4953-BF67-66AC4CEEB12B

P433

Q35629910-EE375EF2-C934-41EC-AF4F-1B48F282A398

P478

Q35629910-ADB76A4F-F110-4A04-B58F-D36E3ABB3B92

P50

Q35629910-095F8DB4-9F60-437C-A2FA-5230116C0717

P577

Q35629910-A49F1945-26A5-412E-AB21-C70C40522CAD

P698

Q35629910-BA5D7451-9F08-454C-8F1F-1F5787E5D752

P356

S40273-015-0288-5

P1433

PharmacoEconomics

P1476

A Systematic Review of the Economic and Humanistic Burden of Gout

@en

P2093

Stephen M Beard

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Epidemiology of gout

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

A concise history of gout and hyperuricemia and their treatment

Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Health-related quality of life in gout: a systematic review

Medication adherence in gout: a systematic review

Gout: an evidence-based review

Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.

P2888

s40273-015-0288-5

P304

1029-1047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-015-0288-5

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25969152

http://www.w3.org/2001/XMLSchema#string